Clinical commentary: Reaching new targets in monotherapy and combination therapy

Research output: Contribution to journalReview articlepeer-review


Cardiovascular disease remains the most common cause of death in the United States. There has, however, been a decline in the age-adjusted death rate for coronary heart disease. This decline may be due, in part, to more aggressive treatment guidelines for treating cardiovascular risk factors, such as hypertension, diabetes, and dyslipidemia. The 2004 update to the National Cholesterol Education Program guidelines have recommended lower low-density lipoprotein cholesterol goals in high-risk patients. Based on the new targets for low-density lipoprotein cholesterol, clinicians will need more efficacious lipid-lowering therapies and improved options for combination therapy. Statin and statin-based combinations have been the mainstays of therapy during the last several years, and as statin utilization increases in the United States, more high-risk patients become exposed to potential statin intolerance. This commentary reviews statin-sparing combinations and use of cholesterol-absorption inhibitors.

Original languageEnglish (US)
Pages (from-to)S34-S38
JournalJournal of Clinical Lipidology
Issue number2
StatePublished - Apr 2008


  • Combination therapy
  • LDL-C goals
  • Monotherapy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Clinical commentary: Reaching new targets in monotherapy and combination therapy'. Together they form a unique fingerprint.

Cite this